Nanolattix Presents at BIO-Europe 2025; T320-ADC Garners Overseas Market Attention
Release time:
2025-11-11
From November 3rd to 5th, 2025, Nanolattix was invited to attend BIO-Europe 2025, held in Vienna, Austria. The company presented numerous前沿 advancements in the fields of Antibody-Drug Conjugates (ADCs) and Radiopharmaceutical Drug Conjugates (RDCs), generating significant interest from the overseas market. Mr. Meng Fanzhuang, Economic and Commercial Counsellor of the Chinese Embassy in Austria, personally visited the delegation of Chinese companies and expressed encouragement for Nanolattix's innovative achievements and international cooperation efforts.
During the conference, Ms. Hao Huahua, General Manager of Nanolattix, systematically introduced the development progress of several innovative drugs. These include the ADC drug T320, the bispecific ADC drug B836, and the RDC drug RT01, all developed based on Nanolattix's proprietary BioLattix biotechnology platform. This presentation showcased the innovation capabilities of Shanxi province in the fields of biotechnology and precision medicine to a global audience of exhibiting companies and professionals. Furthermore, Nanolattix engaged in in-depth discussions and cooperation talks with European industry counterparts regarding the development rights for its core drug, T320, which has already attracted clear interest from multiple parties, marking positive progress in overseas collaboration.
This conference attracted over 2,000 companies and thousands of professionals from the global biopharmaceutical and investment sectors, standing as one of the largest and most influential biotech events in Europe. Through various formats including product exhibitions, technology presentations, and one-on-one meetings, Nanolattix not only comprehensively demonstrated the innovative strength of China's regional pharmaceutical industry but also further expanded cooperation with European partners, continuously driving its innovative drugs towards the global stage.
Tag:
recommend News
Share
